bioAffinity Technologies, Inc. Warrant financials
$0.2600−18.75%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $2.5M | $4.8K |
| Gross profit | $1.9M | $3.4M | $791.6K | $4.3K |
| Gross margin | 31.4% | 36.1% | 31.3% | 90.3% |
| Operating income | -$10.6M | -$9.0M | -$8.0M | -$4.0M |
| Net income | -$14.9M | -$9.0M | -$7.9M | -$8.2M |
| Net margin | −242.0% | −96.6% | −313.4% | −169771.2% |
| Diluted EPS | $-129.90 | $-335.55 | $-409.50 | $-814.50 |
| EBITDA | -$10.1M | -$8.3M | -$7.7M | -$4.0M |
| Operating cash flow | -$9.3M | -$7.3M | -$6.0M | -$4.1M |
| Free cash flow | -$9.4M | -$7.3M | -$6.1M | -$4.3M |
| Diluted shares | 0.1M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $6.4M | $1.1M | $2.8M | $11.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $818.7K | $1.0M | $1.2M | $251.7K |
| Total assets | $11.0M | $6.5M | $8.2M | $12.2M |
| Total liabilities | $3.7M | $3.9M | $3.4M | $1.1M |
| Shareholders' equity | $7.3M | $2.6M | $4.9M | $11.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology